Midazolam buccal - Shire

Drug Profile

Midazolam buccal - Shire

Alternative Names: Buccolam; MHOS; Midazolam hydrochloride oromucosal solution; SHP-615

Latest Information Update: 06 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Therakind; ViroPharma
  • Developer Shire; Therakind
  • Class Antiepileptic drugs; Benzodiazepines; Hypnosedatives; Sleep disorder therapies; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Epilepsy

Most Recent Events

  • 28 Feb 2018 Shire plans a phase III trial for Seizures in USA in 2018
  • 01 Dec 2017 Chemical structure information added
  • 27 Nov 2017 Phase-III clinical trials in Epilepsy (In infants, In children, In adolescents) in Japan (Buccal) (NCT03336645)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top